1. Home
  2. EPRX
  3. EPRX News

Latest EUPRAXIA PHARMACEUTICALS INC (EPRX) News on July 26, 2024

Eupraxia Pharmaceuticals to Present at Controlled Release Society 2024 Annual Meeting and Expo
EPRX

PR Newswire

19 days ago

Eupraxia Pharmaceuticals to Present at Controlled Release Society 2024 Annual Meeting and Expo

Eupraxia Pharmaceuticals to Present at Controlled Release Society 2024 Annual Meeting and Expo
EPRX

CNW Group

19 days ago

Eupraxia Pharmaceuticals to Present at Controlled Release Society 2024 Annual Meeting and Expo

Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Exploring the Rapid Rise of Osteoarthritis" on July 9, 2024
EPRX

CNW Group

23 days ago

Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Exploring the Rapid Rise of Osteoarthritis" on July 9, 2024

A Data-Driven Analysis of Netflix's Streaming Dominance and Future Outlook
EPRX

GuruFocus.com

a month ago

A Data-Driven Analysis of Netflix's Streaming Dominance and Future Outlook

EPRX

Energy Global

a month ago

ANDRITZ to equip new Silvan hydropower plant in Türkiye

Supreme Court Justice Alito talks polarization, his wife talks revenge in secret recordings
EPRX

USA TODAY

a month ago

Supreme Court Justice Alito talks polarization, his wife talks revenge in secret recordings

Indra Energy Drives Sustainability Focus through the Penguins Pledge with the Pittsburgh Penguins
EPRX

Business Wire

a month ago

Indra Energy Drives Sustainability Focus through the Penguins Pledge with the Pittsburgh Penguins

Pacer ETFs Rings in its 9th Anniversary as Firm nears $50 Billion in Assets Under Management
EPRX

Business Wire

a month ago

Pacer ETFs Rings in its 9th Anniversary as Firm nears $50 Billion in Assets Under Management

SEALSQ to Launch Two New Quantum Resistant Chips
EPRX

GlobeNewswire

a month ago

SEALSQ to Launch Two New Quantum Resistant Chips

Shrinking Fed rate cut expectations to keep US Treasury yields elevated: Reuters poll
EPRX

Reuters

a month ago

Shrinking Fed rate cut expectations to keep US Treasury yields elevated: Reuters poll

Global Upstream Bioprocessing Market Analysis Report 2024-2030: A $59.24 Billion Market by 2030, Registering a CAGR of 14.3% from 2024 to 2030
EPRX

GlobeNewswire

a month ago

Global Upstream Bioprocessing Market Analysis Report 2024-2030: A $59.24 Billion Market by 2030, Registering a CAGR of 14.3% from 2024 to 2030

Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders
EPRX

PR Newswire

2 months ago

Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders

Eupraxia Pharmaceuticals to Present Data from the Phase 2 SPRINGBOARD Study in Osteoarthritis of the Knee at EULAR European Congress of Rheumatology 2024
EPRX

PR Newswire

2 months ago

Eupraxia Pharmaceuticals to Present Data from the Phase 2 SPRINGBOARD Study in Osteoarthritis of the Knee at EULAR European Congress of Rheumatology 2024

Eupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
EPRX

CNW Group

2 months ago

Eupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

Eupraxia Pharmaceuticals to Host Virtual KOL Event on EP-104GI Clinical Development Program for Eosinophilic Esophagitis ("EoE") on May 29, 2024
EPRX

PR Newswire

2 months ago

Eupraxia Pharmaceuticals to Host Virtual KOL Event on EP-104GI Clinical Development Program for Eosinophilic Esophagitis ("EoE") on May 29, 2024

Eupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
EPRX

PR Newswire

2 months ago

Eupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

Eupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
EPRX

CNW Group

2 months ago

Eupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

Eupraxia Pharmaceuticals to Present Initial Results from Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024
EPRX

PR Newswire

2 months ago

Eupraxia Pharmaceuticals to Present Initial Results from Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024

Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
EPRX

CNW Group

3 months ago

Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory Board
EPRX

CNW Group

3 months ago

Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory Board

Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024
EPRX

CNW Group

4 months ago

Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024

Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor Conference
EPRX

PR Newswire

4 months ago

Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor Conference

Share on Social Networks: